Rheumatoid arthritis and osteoporosis

Area of Science:

• Rheumatology
• Endocrinology
• Orthopedics

Background:

• Rheumatoid arthritis (RA) is associated with various extra-articular manifestations, including osteoporosis.
• The relationship between RA, osteoporosis, and corticosteroid treatment is complex and debated.
• Understanding bone metabolism in RA is crucial for patient management and preventing fractures.

Purpose of the Study:

• To critically review and discuss controversial issues regarding osteoporosis in rheumatoid arthritis.
• To clarify the role of disease activity, disability, and corticosteroid use in bone loss in RA patients.
• To evaluate the effectiveness of current treatments and identify areas for future research.

Main Methods:

• Literature review and critical analysis of existing studies on osteoporosis and rheumatoid arthritis.
• Discussion of controversial findings related to bone density measurements, fracture risk, and treatment efficacy.
• Synthesis of evidence regarding the impact of corticosteroids and methotrexate on bone health in RA.

Main Results:

• Osteoporosis is more prevalent at the hip and radius than the spine in RA patients.
• Disability, local disease activity, and cumulative corticosteroid dose are key determinants of bone loss.
• Periarticular osteoporosis in early RA reflects disease activity but is not a severity marker in established disease.
• Cumulative corticosteroid dose, not the actual dose, predicts osteoporotic fractures; quantitative tomography findings require careful interpretation.
• Anti-resorbing drugs do not appear to affect RA erosions; stress fractures are underdiagnosed.
• Low-dose methotrexate's bone toxicity is unclear, but spontaneous fractures and lower extremity pain may be more frequent.

Conclusions:

• Osteoporosis is not a common systemic extra-articular manifestation of RA.
• Cumulative corticosteroid dose is a critical factor in corticosteroid-induced osteoporotic fractures.
• Further prospective studies are needed to clarify methotrexate's effects on bone and confirm the frequency of stress fractures in RA.